Last10K.com

Acelity L.P. Inc. (1557939) SEC Filing 10-Q Quarterly report for the period ending Thursday, March 31, 2016

Acelity L.P. Inc.

CIK: 1557939



ACELITY L.P. INC. REPORTS
FIRST QUARTER FINANCIAL RESULTS FOR 2016
Total Revenue for the First Quarter of 2016 Grows 3.0% on a Constant Currency Basis


First Quarter Financial Highlights

Revenue for the first quarter of 2016 of $451.4 million, grew 1.6% as reported on a GAAP basis and 3.0% on a constant currency basis, from the prior-year period

Revenue from Advanced Wound Therapeutics ("AWT") grew 0.5% as reported on a GAAP basis and 2.1% on a constant currency basis, led by solid volume growth in advanced wound devices compared to the prior-year period

Revenue from Regenerative Medicine ("RM") grew 5.5% as reported on a GAAP basis and 5.8% on a constant currency basis, due primarily to higher volumes associated with breast reconstruction procedures

Net loss was $26.0 million, as reported on a GAAP basis, up from $4.5 million net loss in the prior-year period, due primarily to the impact of foreign currency exchange rate movements on the revaluation of our Term E-1 EURO loan

Adjusted EBITDA1 of $161.0 million, declined 2.9% as reported from the prior-year period and 2.2% on a constant currency basis primarily due to investments being made in our franchise structure and sales force to drive growth


Operational Highlights

The Company refinanced its Senior Term E-2 Credit Facility due November 4, 2016 with the proceeds from the offering of $400.0 million of 7.875% First Lien Senior Secured Notes due 2021.  Additionally, the Company extended a portion of its Revolving Credit Facility by one year to November 4, 2017.

Announced a partnership with Mediq to exclusively distribute Acelity’s advanced wound care and regenerative medicine portfolio in Denmark, Finland, Norway and Sweden. The alliance with Mediq, a leading homecare and medical device delivery company, offers Acelity access to Mediq’s specialized knowledge, expertise and network in the region and allows Acelity to expand operations in the post-acute environment.


Joe Woody, President and Chief Executive Officer, commented, “We begin 2016 with significant momentum, having achieved our sixth consecutive quarter of organic revenue growth driven by strong volumes in advanced wound devices, significant growth in sales of expansion products, and double digit growth in revenue from breast reconstruction procedures. Looking ahead to the remainder of the year, we will continue to invest in our people, our innovation pipeline and our business to strengthen our unique therapeutic portfolio to deliver cost-effective solutions to patients around the world.”





The following information was filed by Acelity L.P. Inc. on Tuesday, May 3, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Acelity L.P. Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Acelity L.P. Inc..

Continue

Assess how Acelity L.P. Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Acelity L.P. Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income (loss)
Condensed Consolidated Statements Of Comprehensive Income (loss) (parenthetical)
Condensed Consolidated Statements Of Operations
Accumulated Other Comprehensive Income (loss)
Accumulated Other Comprehensive Income (loss) (details)
Accumulated Other Comprehensive Income (loss) (tables)
Acquisitions And Divestitures (tables)
Acquisitions And Divestitures Acquisitions (details)
Acquisitions And Divestitures Acquisitions And Divestitures
Commitments And Contingencies
Commitments And Contingencies (details)
Derivative Financial Instruments And Fair Value Measurements
Derivative Financial Instruments And Fair Value Measurements (tables)
Derivative Financial Instruments And Fair Value Measurements - Derivative Financial Instruments (details)
Derivative Financial Instruments And Fair Value Measurements - Fair Value And Balance Sheet Locations (details)
Derivative Financial Instruments And Fair Value Measurements - Gain (loss) On Derivatives (details)
Guarantor Condensed Consolidating Financial Statements
Guarantor Condensed Consolidating Financial Statements (tables)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Balance Sheet (details)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Cash Flow (details)
Guarantor Condensed Consolidating Financial Statements - Condensed Consolidated Statement Of Operations And Comprehensive Income (loss) (details)
Long-term Debt
Long-term Debt (details)
Long-term Debt (tables)
Segment Information
Segment Information (details)
Segment Information (tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Supplemental Balance Sheet Data
Supplemental Balance Sheet Data (tables)
Supplemental Balance Sheet Data - Accounts Receivable, Net (details)
Supplemental Balance Sheet Data - Inventories, Net (details)

Material Contracts, Statements, Certifications & more

Acelity L.P. Inc. provided additional information to their SEC Filing as exhibits

CIK: 1557939
Form Type: 10-Q Quarterly Report
Accession Number: 0001557939-16-000084
Submitted to the SEC: Tue May 03 2016 9:56:35 PM EST
Accepted by the SEC: Wed May 04 2016
Period: Thursday, March 31, 2016
Industry: Surgical And Medical Instruments And Apparatus

External Resources:

Bookmark the Permalink:
https://last10k.com/sec-filings/1557939/0001557939-16-000084.htm